Indivior Pharmaceuticals (INDV) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.32
- Estimate
- $1.13
- Surprise
- +17.2%
- Revenue (period 2026-09-30)
- $356.0M
- Score at report (before → after)
- 6.8 → 6.8/10
Revenue source: xbrl.
How the report landed
Indivior Pharmaceuticals (INDV) beat the $1.13 estimate with adjusted EPS of $1.32 — a large 17.2% upside surprise. TrendMatrix's engine moved from Hold (6.8/10) to Buy (Wait) at 6.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates INDV Strong Buy at 6.9/10.
What supports the rating
- High-quality business
- Attractive valuation
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $28.15
- Entry target
- $28.15
- Price target
- $42.07
- Stop
- $26.18
- Upside to target
- +49.4%
- Reward-to-risk
- 4.5:1
The stock trades at 10.2× trailing but 8.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 1.7× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
INDV at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $4.28B
- P/E (fwd)
- 8.0
- P/E (ttm)
- 10.2
- 52-week range
- $27.68–$42.81
- Off 52-week high
- 34.2%
- RSI (14)
- 55
- Volume vs avg
- 1.66×
- Score today
- 6.9/10